{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:40:54Z","timestamp":1792773654414,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"publisher","award":["2024SCE58"],"award-info":[{"award-number":["2024SCE58"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.gendis.2026.102038","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:19:00Z","timestamp":1768324740000},"page":"102038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A panoramic study of circulating tumor DNA in diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"14","author":[{"given":"Ruoyun","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8629-7532","authenticated-orcid":false,"given":"Wanyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2931-5762","authenticated-orcid":false,"given":"Lintao","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.gendis.2026.102038_bib1","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/jpm11121384","article-title":"Prognostic value of histone modifying enzyme EZH2 in RCHOP-treated diffuse large B-cell lymphoma and high grade B-cell lymphoma","volume":"11","author":"Petronilho","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.gendis.2026.102038_bib2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/bloodadvances.2023011997","article-title":"Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas","volume":"8","author":"Shukla","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.gendis.2026.102038_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/bjh.17894","article-title":"Tracking the evolution of untreated high-intermediate\/high-risk diffuse large B-cell lymphoma by circulating tumour DNA","volume":"196","author":"Zhang","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70193","article-title":"Minimal residual disease detection: implications for clinical diagnosis and cancer patient treatment","volume":"6","author":"Song","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.gendis.2026.102038_bib5","article-title":"Minimal residual disease detection in lymphoma: methods, procedures and clinical significance","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.gendis.2026.102038_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103348","article-title":"Measurable residual disease in hematologic malignancies: a biomarker in search of a standard","volume":"86","author":"Chandhok","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.gendis.2026.102038_bib7","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10238-021-00718-8","article-title":"Prognostic value of circulating tumor DNA in lymphoma: a meta-analysis","volume":"22","author":"Yao","year":"2022","journal-title":"Clin Exp Med"},{"issue":"7","key":"10.1016\/j.gendis.2026.102038_bib9","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/bloodadvances.2024014136","article-title":"Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels","volume":"9","author":"Moia","year":"2025","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.gendis.2026.102038_bib10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.gendis.2026.102038_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/mc.23476","article-title":"Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: based on next generation sequencing","volume":"62","author":"Hou","year":"2023","journal-title":"Mol Carcinog"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70174","article-title":"Integrating multi-omics features enables non-invasive early diagnosis and treatment response prediction of diffuse large B-cell lymphoma","volume":"15","author":"Zhang","year":"2025","journal-title":"Clin Transl Med"},{"issue":"11","key":"10.1016\/j.gendis.2026.102038_bib13","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.clml.2024.06.006","article-title":"Molecular disease monitoring in patients with relapsed\/refractory B-cell lymphoma receiving anti-CD19 CAR T-cell therapy","volume":"24","author":"Colton","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib14","first-page":"11","article-title":"Richter syndrome: novel insights into the biology of transformation","volume":"142","author":"Parry","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12916-022-02562-3","article-title":"Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib16","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jmoldx.2017.07.007","article-title":"Determination of molecular subtypes of diffuse large B-cell lymphoma using a reverse transcriptase multiplex ligation-dependent probe amplification classifier: a CALYM study","volume":"19","author":"Bob\u00e9e","year":"2017","journal-title":"J Mol Diagn"},{"issue":"10","key":"10.1016\/j.gendis.2026.102038_bib17","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1016\/j.clml.2025.05.003","article-title":"Minimal residual disease testing for diffuse large B cell lymphoma","volume":"25","author":"Atout","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.gendis.2026.102038_bib18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"28","key":"10.1016\/j.gendis.2026.102038_bib19","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.gendis.2026.102038_bib20","doi-asserted-by":"crossref","first-page":"472.e1","DOI":"10.1016\/j.jtct.2023.03.009","article-title":"Cell-free DNA dynamic concentration and other variables are predictors of early progression after chimeric antigen receptor T cell therapy in patients with diffuse large B cell lymphoma","volume":"29","author":"Bastos-Oreiro","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.gendis.2026.102038_bib21","first-page":"827","article-title":"Efficacy and safety analysis of the OR-CHOP regimen for the treatment of MCD subtype diffuse large B cell lymphoma in the real-world setting","volume":"45","author":"Yin","year":"2024","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"14","key":"10.1016\/j.gendis.2026.102038_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18576","article-title":"Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA","volume":"28","author":"Chen","year":"2024","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70150","article-title":"Revealing the heterogeneity of treatment resistance in less-defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy","volume":"15","author":"Hua","year":"2025","journal-title":"Clin Transl Med"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.2023022020","article-title":"Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA","volume":"143","author":"Heger","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.gendis.2026.102038_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/ejh.13736","article-title":"Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma","volume":"108","author":"Fu","year":"2022","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102038_bib26","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.7150\/jca.69639","article-title":"Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma","volume":"13","author":"Bang","year":"2022","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bjh.19458","article-title":"Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease","volume":"205","author":"Alcoceba","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13148-022-01344-1","article-title":"5-Hydroxymethylation alterations in cell-free DNA reflect molecular distinctions of diffuse large B cell lymphoma at different primary sites","volume":"14","author":"Shen","year":"2022","journal-title":"Clin Epigenetics"},{"issue":"27","key":"10.1016\/j.gendis.2026.102038_bib29","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib31","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00277-020-04008-3","article-title":"Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas","volume":"99","author":"Hur","year":"2020","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.gendis.2026.102038_bib32","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1182\/bloodadvances.2021004528","article-title":"Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab","volume":"5","author":"Bruscaggin","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.gendis.2026.102038_bib33","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/s41375-025-02688-2","article-title":"Integration of [(18)F] FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma","volume":"39","author":"Dondolin","year":"2025","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.gendis.2026.102038_bib34","first-page":"638","article-title":"Clinical application of circulating tumor DNA in diffuse large B-cell lymphoma: review","volume":"29","author":"Chen","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"12","key":"10.1016\/j.gendis.2026.102038_bib35","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1007\/s00277-024-05844-3","article-title":"Analysis of CCND3 mutations in diffuse large B-cell lymphoma","volume":"103","author":"Hua","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13059-023-02905-0","article-title":"NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization","volume":"24","author":"Narang","year":"2023","journal-title":"Genome Biol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102038_bib37","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022: a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.gendis.2026.102038_bib39","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.gendis.2026.102038_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102038_bib41","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.gendis.2026.102038_bib42","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.gendis.2026.102038_bib43","first-page":"805","article-title":"Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"44","author":"Zhou","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.gendis.2026.102038_bib44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/hematology.2021000312","article-title":"Does MRD have a role in the management of iNHL?","volume":"2021","author":"Giudice","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"18","key":"10.1016\/j.gendis.2026.102038_bib45","doi-asserted-by":"crossref","first-page":"9982","DOI":"10.3390\/ijms25189982","article-title":"Characterizing the cell-free transcriptome in a humanized diffuse large B-cell lymphoma patient-derived tumor xenograft model for RNA-based liquid biopsy in a preclinical setting","volume":"25","author":"Decruyenaere","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gendis.2026.102038_bib46","doi-asserted-by":"crossref","first-page":"10797","DOI":"10.2147\/OTT.S275334","article-title":"Genotyping on ctDNA identifies shifts in mutation spectrum between newly diagnosed and relapse\/refractory DLBCL","volume":"13","author":"Liu","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"18","key":"10.1016\/j.gendis.2026.102038_bib47","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.7150\/jca.60390","article-title":"Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r\/r diffuse large B cell lymphoma precise treatment","volume":"12","author":"Zhou","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.gendis.2026.102038_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1283194","article-title":"Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review","volume":"13","author":"He","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib49","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/ejh.14191","article-title":"Noninvasive minimal residual disease assessment in relapsed\/refractory large B-cell lymphoma using digital droplet PCR","volume":"112","author":"Heger","year":"2024","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib50","first-page":"583","article-title":"Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas","volume":"5","author":"Arffman","year":"2024","journal-title":"M\u00e9d Sur"},{"issue":"5","key":"10.1016\/j.gendis.2026.102038_bib51","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11864-024-01201-8","article-title":"Circulating tumor DNA in diffuse large B-cell lymphoma: from bench to bedside?","volume":"25","author":"Cherng","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"10.1016\/j.gendis.2026.102038_bib52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12308-023-00566-3","article-title":"A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse","volume":"16","author":"Yan","year":"2023","journal-title":"J Hematop"},{"issue":"4","key":"10.1016\/j.gendis.2026.102038_bib53","first-page":"507","article-title":"Circulating free RNA as a therapeutic evaluation in diffuse large B-cell lymphoma: a case series from the Indonesian cancer center","volume":"56","author":"Sutandyo","year":"2024","journal-title":"Acta Med Indones"},{"issue":"17","key":"10.1016\/j.gendis.2026.102038_bib54","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.2020009432","article-title":"CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma","volume":"137","author":"Baird","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.gendis.2026.102038_bib55","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1200\/JCO.20.02573","article-title":"Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma","volume":"39","author":"Alig","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib56","first-page":"1690","article-title":"(18)F-FDG PET\/CT metabolic parameters and circulating tumour DNA mutation abundance in diffuse large B-cell lymphoma: correlation and survival analysis","volume":"31","author":"Xu","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"9","key":"10.1016\/j.gendis.2026.102038_bib57","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3324\/haematol.2021.279908","article-title":"A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas","volume":"107","author":"Wang","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib58","first-page":"1917","article-title":"Clinical application and research progress of circulating tumor DNA in diffuse large B-cell lymphoma: review","volume":"30","author":"Zhang","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"6","key":"10.1016\/j.gendis.2026.102038_bib59","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s11899-022-00677-1","article-title":"Circulating tumor DNA in lymphoma","volume":"17","author":"Thiruvengadam","year":"2022","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:48:59Z","timestamp":1792770539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304226000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2027,2]]}},"alternative-id":["S2352304226000103"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102038","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A panoramic study of circulating tumor DNA in diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102038"}}